Sutro Biopharma (STRO) Income towards Parent Company (2017 - 2025)

Sutro Biopharma (STRO) has 9 years of Income towards Parent Company data on file, last reported at -$46.8 million in Q4 2025.

• For the quarter ending Q4 2025, Income towards Parent Company rose 35.46% year-over-year to -$46.8 million; the trailing twelve-month figure through Dec 2025 stood at -$182.7 million (up 19.66% YoY), and the FY2025 full-year result was -$191.1 million, up 15.99% from the prior year.
• Income towards Parent Company climbed to -$46.8 million in Q4 2025, from -$56.9 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $31.1 million in Q4 2023 to a low of -$72.4 million in Q4 2024.
• A 5-year average of -$36.6 million and a median of -$38.8 million in 2022 frame the typical range for Income towards Parent Company.
• Across the five-year window, Income towards Parent Company surged 189.78% in 2023 and sank 333.26% in 2024, its largest moves.
• Tracing STRO's Income towards Parent Company over 5 years: stood at -$38.1 million in 2021, then rose by 9.26% to -$34.6 million in 2022, then surged by 189.78% to $31.1 million in 2023, then sank by 333.26% to -$72.4 million in 2024, then surged by 35.46% to -$46.8 million in 2025.
• Business Quant data shows STRO's Income towards Parent Company at -$46.8 million in Q4 2025, -$56.9 million in Q3 2025, and -$11.5 million in Q2 2025.